gynecologic cancer

Study Finds HPV Screening May Be More Sensitive Than Pap Test for Detecting Cervical Cancer

The main goal of cervical screening programs is to detect and treat precancer before the cancer develops. Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer. However, reports of rare HPV-negative, cytology-positive cancers are motivating the continued use of...

lymphoma

Association of Event-Free Survival at 24 Months With Overall Survival in Peripheral T-Cell Lymphoma

In a study reported in the Journal of Clinical Oncology, Maurer et al found that event-free survival at 24 months (EFS24) was associated with prolonged subsequent overall survival among patients with peripheral T-cell lymphoma (PTCL). Study Details The study involved patients with systemic PTCL...

solid tumors

Combination Therapy for Advanced Lung and Thymus Carcinoids

A European phase II trial has shown activity of long-acting pasireotide, everolimus (Afinitor), or their combination in patients with advanced lung and thymus carcinoids. These study findings were reported by Ferolla et al in The Lancet Oncology. Study Details In the study, 124 patients from 36...

lymphoma

FDA Approves Brentuximab Vedotin for Primary Cutaneous Anaplastic Large Cell Lymphoma

Today, the U.S. Food and Drug Administration (FDA) granted regular approval to brentuximab vedotin (Adcetris) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides who have received prior systemic therapy. ALCANZA...

hematologic malignancies

FDA Approves Letermovir for Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Stem Cell Transplant Patients

Today, the U.S. Food and Drug Administration (FDA) approved letermovir (Prevymis) once-daily tablets for oral use and injection for intravenous infusion. Letermovir is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic...

breast cancer

Higher Risk of Breast Cancer Does Not Motivate Cancer Screening in Many Women

Some women, because of genetic predisposition, personal, or family history, have a higher-than-average lifetime risk of developing breast cancer. For those women, earlier magnetic resonance imaging (MRI) is recommended for cancer screening. But according to new findings presented at the American...

colorectal cancer

Association of Tumor HER3 Expression With Treatment Outcome in Advanced Colorectal Cancer

In a study reported in JAMA Oncology, Seligmann et al found that higher tumor HER3 messenger RNA expression among patients with RAS wild-type tumors was associated with a better outcome with panitumumab (Vectibix) plus irinotecan vs irinotecan alone among patients with advanced colorectal cancer in ...

supportive care

Predictors of Posthospital Care Transitions in Advanced Cancer

In a study reported in the Journal of Clinical Oncology, Lage and colleagues found that among patients with advanced cancer who had an unplanned hospital admission, those discharged to hospice or post–acute care facilities had a worse symptom burden and physical function and worse survival...

hepatobiliary cancer

Internal Radiotherapy vs Kinase Inhibitor in Advanced Hepatocellular Carcinoma

A French phase III trial has shown no significant survival difference between selective internal radiotherapy with yttrium-90 resin microspheres vs sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. The findings were reported by Vilgrain et al in The Lancet Oncology. Study...

solid tumors

Characteristics of Recurrence in Stage I to III Midgut Neuroendocrine Tumors

In a study reported in the Journal of the National Cancer Institute, Cives et al found that postsurgical relapse occurred in 31% of patients with stage I to III midgut neuroendocrine tumors over long-term follow-up, with liver, mesentery, and pelvic lymph nodes being the main sites of relapse....

prostate cancer

HSD3B1 Variant and Response to Nonsteroidal CYP17A1 Inhibition in Castration-Resistant Prostate Cancer

As reported in JAMA Oncology by Almassi et al, extragonadal androgen ablation with the nonsteroidal CYP17A1 inhibitor ketoconazole improved outcome in men with metastatic castration-resistant prostate cancer according to the number of inherited HSD3B1 (1245C) alleles. HSD3B1 (1245C) is associated...

issues in oncology

ASCO Cites Evidence That Alcohol Is Linked to Cancer, Calls for Reduced Alcohol Consumption

Alcohol use—whether light, moderate, or heavy—is linked with increasing the risk of several leading cancers, including those of the breast, colon, esophagus, and head and neck, according to evidence gathered by ASCO. In a statement released November 7 identifying alcohol as a definite...

breast cancer

Long-Term Follow-up of Cardiac Function After Adjuvant Therapy With Trastuzumab in Early Breast Cancer

As reported by Ganz et al in the Journal of Clinical Oncology, long-term follow-up of patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-31/NRG Oncology trial showed no worsening of cardiac function or quality of life with the addition of adjuvant trastuzumab...

lung cancer

FDA Approves Alectinib for ALK-Positive Metastatic NSCLC

On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to alectinib (Alecensa) for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December 2015,...

hematologic malignancies

FDA Approves Vemurafenib for Certain Patients With Erdheim-Chester Disease

On November 6, the U.S. Food and Drug Administration (FDA) expanded the approval of vemurafenib (Zelboraf) to include the treatment of certain adult patients with Erdheim-Chester disease (ECD), a rare cancer of the blood. Vemurafenib is indicated to treat patients whose cancer cells have a specific ...

gynecologic cancer

FDA Accepts sBLA for Bevacizumab as a Front-Line Treatment for Advanced Ovarian Cancer

On October 25, Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel), followed by bevacizumab alone, for the front-line ...

issues in oncology

Hospital Emergency Department Practices for Treating Older Adults With Cancer

A new study published by Lipitz-Snyderman et al in JNCCN–Journal of the National Comprehensive Cancer Network found that among patients presenting to the emergency department, those with cancer, especially those aged 75 years or older, are more likely to be admitted to the hospital—and...

leukemia

Fat Cells May Inactivate Chemotherapeutic Drug and Contribute to Poorer Survival in ALL

It is well established that obesity increases the risk for cancer mortality, although no mechanisms have been proven to explain the reason for this association. Now a laboratory study investigating how obesity might alter the effectiveness of daunorubicin in the treatment of acute lymphoblastic...

issues in oncology

Worldwide Cancer Incidence and Mortality Among Persons Aged 20 to 39 in 2012

In a study reported in The Lancet Oncology, Fidler et al found that cancer burden was higher worldwide among women vs men aged 20 to 39 in 2012 and that the incidence was higher but mortality lower in very high vs low Human Development Index regions. Study Details The study involved data from the ...

gynecologic cancer

Novel Adverse Genomic Rearrangement Signature in High-Grade Serous Ovarian Cancer

As reported by Hillman et al in the Journal of the National Cancer Institute, a novel genomic rearrangement signature associated with poorer overall survival has been identified in high-grade serous ovarian cancer. Study Details In the study, clinical data and whole-genome sequencing results were ...

head and neck cancer

Combination Therapy for Advanced BRAF V600–Mutant Anaplastic Thyroid Cancer

A phase II study reported by Subbiah et al in the Journal of Clinical Oncology indicates activity of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. Study Details In the study,...

leukemia

MicroRNA Expression–Based Risk Model for Pediatric Acute Myeloid Leukemia

As reported in the Journal of Clinical Oncology, Lim et al have identified a microRNA expression–based risk model associated with event-free survival in pediatric acute myeloid leukemia (AML). The study involved comprehensive miRNA sequencing of 1,362 pediatric AML samples, consisting of...

solid tumors

Factors Associated With Outcome in Pediatric Adrenocortical Tumors

In a St. Jude Adrenocortical Tumor Registry and Children’s Oncology Group study reported in the Journal of Clinical Oncology, Pinto et al found that a positive Ki67 labeling index was associated with a poorer outcome in children with adrenocortical tumors independent of germline TP53 mutation ...

lung cancer

Novel Tyrosine Kinase Inhibitor for ALK- or ROS1-Rearranged NSCLC

A phase I trial has shown that the ALK and ROS1 tyrosine kinase inhibitor lorlatinib is active in patients with advanced ALK- or ROS1-positive non–small cell lung cancer (NSCLC), including those with central nervous system (CNS) metastases and failure on at least two prior tyrosine kinase...

lung cancer

CHEST 2017: American College of Chest Physicians Unveils New Lung Cancer Screening Guidelines

Low-dose computed tomography (CT) screening for lung cancer has become standard practice, mostly due to the results of the National Lung Screening Trial. Related evidence continues to evolve, informing the benefits and risks of low-dose CT in clinical practice. Mazzone et al presented new ...

lung cancer

CHEST 2017: Gender, Language, and Treatment Setting as Barriers in Screening and Patient Care in Lung Cancer

Two new studies from CHEST 2017, held recently in Toronto, reveal disparities in lung cancer screening and care that may impact detection as well as mortality and survival rates in the disease. Risk Status and Screening The first study from Lahey Hospital and Medical Center in Burlington,...

issues in oncology

Changes in Uninsured Status Among Nonelderly Cancer Patients Under the Affordable Care Act

In a research letter in JAMA Oncology, Soni et al reported reductions in the proportion of nonelderly adult cancer patients who were uninsured between 2010 and 2013 vs 2014, after institution of the Affordable Care Act (ACA). Study Details The study used data from the Surveillance, Epidemiology,...

head and neck cancer

ASCO Endorses ASTRO Guideline on Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma

As reported in the Journal of Clinical Oncology by Harry Quon, MD, of Johns Hopkins University School of Medicine, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline on radiation therapy for...

multiple myeloma

Results From Phase III ARROW Study of Once-Weekly Carfilzomib in Relapsed/Refractory Multiple Myeloma

On October 23, topline results of the phase III ARROW trial were announced, showing carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone allowed relapsed and refractory multiple myeloma patients to live 3.6 months longer without their disease worsening than...

skin cancer

Adjuvant Dabrafenib/Trametinib Combination Granted FDA Breakthrough Therapy Designation for Stage III Melanoma With BRAF V600 Mutation

On October 23, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following...

lung cancer

PanCan Risk Model for Lung Cancer Screening

Results of the Pan-Canadian Early Detection of Lung Cancer (PanCan) study, reported in The Lancet Oncology by Tammemagi et al, indicate that the PanCan risk model is effective in identifying persons found to have early-stage lung cancer on low-dose computed tomography (CT) screening. Study Details ...

breast cancer

Complications and Patient Satisfaction After Breast Reconstruction in Women Receiving Radiotherapy

In a prospective cohort study reported by Jagsi et al in the Journal of the National Cancer Institute, autologous reconstruction was associated with fewer complications and greater patient satisfaction vs implant approaches in women receiving postmastectomy radiotherapy. Study Details The...

survivorship

New Persistent Opioid Use After Curative-Intent Cancer Surgery

A study reported by Lee et al in the Journal of Clinical Oncology indicates that approximately 10% of patients undergoing curative-intent surgery for cancer become new persistent opioid users. Study Details The study involved data from 68,463 patients from a national data set of insurance claims...

hepatobiliary cancer

The Liver Meeting: Daily Aspirin May Reduce Risk for Hepatitis B Virus–Related Liver Cancer

A new study presented at The Liver Meeting, held by the American Association for the Study of Liver Diseases, found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus (HBV)–related liver cancer (Abstract 223). According to AASLD’s...

hepatobiliary cancer

The Liver Meeting: Direct-Acting Antiviral Medications as Hepatitis C Treatment May Reduce Risk of Liver Cancer

A new study presented at The Liver Meeting—held by the American Association for the Study of Liver Diseases—found that eradication of the hepatitis C virus induced by direct-acting antiviral medications is associated with a 71% reduction in the risk of liver cancer (Abstract 142)....

survivorship

Long-Term Survivors of Childhood Cancer Prone to ‘Job Lock’ due to Worries About Losing Health Insurance

The results of a national cancer survey reveal a significant number of childhood cancer survivors are worried about keeping their health insurance, to the point of letting it affect their career decisions. The findings were published by Kirchhoff et al in JAMA Oncology. Anne Kirchhoff, PhD,...

prostate cancer

HSD3B1 Genotype and Outcomes With ADT After Radiotherapy for Localized Prostate Cancer

In a study reported in JAMA Oncology, Hearn et al found that the presence of the HSD3B1 (1245C) allele was associated with more rapid development of metastases in patients receiving androgen-deprivation therapy for biochemical recurrence after primary radiation therapy for localized prostate...

lymphoma

Final Results of German Trial of PET-Guided Treatment in Advanced Hodgkin Lymphoma

Final results of the German Hodgkin Study Group phase III HD18 trial, reported in The Lancet by Borchmann et al, showed no benefit of adding rituximab (Rituxan) to escalated BEACOPP (eBEACOPP; bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) in...

breast cancer

ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer

As reported by Catherine Van Poznak, MD, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario (CCO) have collaborated in providing a focused update for the ASCO clinical practice guideline on the role of bone-modifying agents in...

breast cancer

ASHG 2017: Quantifying Breast Cancer Risk Based on Rare Variants and Background Risk

Rare variants combined with background genetic risk factors may account for many unexplained cases of familial breast cancer, and knowing the specific genes involved could inform choice of prevention and treatment strategies, according to findings presented in a plenary session at the American...

lymphoma

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to acalabrutinib (Calquence) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma is a particularly aggressive cancer,” said Richard...

issues in oncology

Racial/Ethnic Disparities in Cancer-Specific Survival in California

In a study using California Cancer Registry data reported in the Journal of Clinical Oncology, Ellis et al found that the stage at diagnosis was the greatest contributor to racial/ethnic disparities in cancer-specific survival, with neighborhood socioeconomic status and marital status also being...

gynecologic cancer

CD8-Positive Tumor-Infiltrating Lymphocytes and Survival in High-Grade Serous Ovarian Cancer

As reported in JAMA Oncology by Goode et al in the Ovarian Tumor Tissue Analysis Consortium, higher levels of cytotoxic CD8-positive tumor-infiltrating lymphocytes were associated with significantly improved overall survival among women with high-grade serous ovarian carcinomas. Study Details The ...

issues in oncology

AACR-NCI-EORTC: Rising Number of Seamless Clinical Trials in Oncology

The number of early-phase trials in oncology that adopted a seamless approach—as opposed to a traditional trial approach with defined phase I, II, and III plans—is rising, with data from the majority of them presented after 2014, according to a study presented by Barata et al at the...

solid tumors

AACR-NCI-EORTC: NCI-MATCH Reaches Central Patient-Screening Goal

The National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) clinical trial has achieved the goal of screening nearly 6,000 patients in just under 2 years, according to data presented by Chen et al at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer...

solid tumors

AACR-NCI-EORTC: Noninvasive Computational Imaging Approach May Help Predict Response to Immunotherapy

A computational imaging-based signature of immune-cell infiltration in and around a tumor could predict patients’ responses to treatment with anti–programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immunotherapies, according to data from a study presented by Sun et...

colorectal cancer

AACR-NCI-EORTC: Colorectal Cancer Test Could Detect Early Cancer-Causing Genetic Biomarkers With High Degree of Sensitivity

An investigational test that screens for colorectal cancer could detect genetic mutations that are indicative of the disease with a high degree of sensitivity and specificity, according to results of a study presented by Powell et al at the AACR-NCI-EORTC International Conference on Molecular...

lymphoma

FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma

On October 18, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma...

health-care policy

Gary Gilliland, MD, PhD, Testifies Before Congress on NIH Funding System

Gary Gilliland, MD, PhD, President and Director of Fred Hutchinson Cancer Research Center, recently delivered the following testimony and answered questions from members of the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. His remarks...

head and neck cancer

AACR-NCI-EORTC: Tipifarnib Shows Durable Antitumor Activity in HRAS-Mutant Head and Neck Cancer

Preliminary results from a phase II open-label trial of tipifarnib, a farnesyltransferase inhibitor, in patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC) were presented by Alan L. Ho, MD, PhD, of Memorial Sloan Kettering Cancer Center, at the AACR-NCI-EORTC International...

Advertisement

Advertisement



Advertisement